Overview
Rejuvenate Biomed is a science-based healthy aging company dedicated to the discovery and development of therapeutics to impact the onset of multiple age-related diseases. The company is conducting a Phase 2 clinical trial of its lead asset RJx-01, a first-in-class multi-pathway therapeutic targeting COPD-induced sarcopenia and muscle weakness, with topline data expected by year-end 2026.
Key people
In the news
- Rejuvenate Biomed is looking forward to the Cell Symposium: Hallmarks of Aging in Seville! Our CSO, Dr. Evi Mercken, is attending this leading scientific meeting, which brings together researchers and innovators working to better understand the biology of aging. She looks forward to meet her peers, contribute to the in-depth conversations and explore new collaborations. The symposium offers a great opportunity to exchange ideas, learn from the latest discoveries in the field, and connect with fellow scientists who share a common
- We're excited to be part of #OPINNO 2026 at Hasselt University. Our colleague Nick Smisdom, PhD, Lead DevOps Engineering & Data Architecture and ICT Lead, will present about working at Rejuvenate Biomed and the many career opportunities within biotech in general. 📅 6 October 2026 🕐 13:10 – 13:20 | Medical Biotech 🎤 Nick Smisdom | Rejuvenate Biomed Following the presentation, Nick will join a roundtable discussion with students to answer questions about careers in biotech, innovation, data, technology, and what it's
- Inspired by #EuGMS2026 in Lille! It was a pleasure for Rejuvenate Biomed, represented by Jeroen Aerssens, PhD, and Ana Cristy Ugarte Guzman, MD, to join clinicians, healthcare professionals and researchers dedicated to advancing healthy ageing at the European Geriatric Medicine Society conference in Lille. Among the many insightful discussions, one theme that resonated with us was the importance of muscle strength and function for healthy ageing. In his opening keynote on the Biological Basis of Functionality, Prof. Bruno
- Rejuvenate Biomed is heading to Lille for the European Geriatric Medicine Society (#EuGMS) Congress 2026. We are pleased to share that Jeroen Aerssens, Chief Development Officer, and Ana Cristy Ugarte Guzman, MD, Trial Physician will represent our company. 📅 September 16-18 | Lille, France 👉 Visit our Late Breaking News Digital Poster: RJx-01 Improves Recovery of Muscle Strength and Function Following Disuse: Rationale for a Phase 2 Trial in Osteosarcopenia Jeroen and Ana look forward to engaging with the geriatric medicine
- July 4th is World Sarcopenia Day Sarcopenia, the progressive loss of muscle strength and function, is no longer just a consequence of ageing. It is a serious, underdiagnosed condition that drives frailty, disability, and loss of independence, with major implications for patients and healthcare systems worldwide. On #WorldSarcopeniaDay, it is important to recognize that addressing sarcopenia requires more than awareness, it requires action. While developing effective treatments for patients with established sarcopenia is
- BIO2026: a week full of inspiration, insights, and meaningful connections The BIO International Convention once again proved to be the world’s leading gathering for biotech, pharma, and investors, and we were proud to be part of it. At Rejuvenate Biomed, we came back energized by: 🔹 Inspiring panel discussions and expert presentations 🔹 New insights and valuable learnings 🔹 Engaging and productive meetings with current and new stakeholders We were particularly encouraged by the strong interest in both: ✅ RJx-01, in clinical
- Team spirit in action 💪✨ At Rejuvenate Biomed, we believe that strong collaboration goes beyond the workplace. We spent a wonderful time together, filled with creativity and connection that strengthen the bonds that drive our mission forward. Moments like these remind us that innovation starts with people. #Teamwork #RejuvenateBiomed #HealthyAging #StrongerTogether
- Rejuvenate Biomed is ready for #BIO2026! We are excited to actively participate in the world’s largest biotechnology convention, bringing together leaders from biotech, pharma, and the investment community. Our team will be represented by: 👉 Ann Belien, PhD, Founder & CEO 👉 Lizzy-Anne (Lisiane) Neven, CFO 👉 David Brooks, PhD, Business Development Lead We’re especially proud that Ann will be speaking in two inspiring sessions: 📅 22 June 2026 | 4:15 – 5:15 PM Reclaiming the Impossible: Biotech Leaders on Breaking Through in
Something wrong or missing? Send an update. Fixed within 24 hours.